PHI with Bechterew's disease (Ankylosing Spondylitis)
How does this condition affect your private health insurance?
Bechterewsche Erkrankung, also known as Ankylosing Spondylitis (AS), is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints. It leads to persistent pain and stiffness, often worse after periods of rest. Over time, inflammation can cause new bone formation, leading to fusion of vertebrae, resulting in a rigid 'bamboo spine' and significant loss of mobility. AS can also affect other joints, eyes (uveitis), skin (psoriasis), and bowel (inflammatory bowel disease). It is a progressive condition with a strong genetic predisposition, notably linked to the HLA-B27 gene. Early diagnosis and treatment are crucial to manage symptoms and slow disease progression.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Insidious onset, typically developing gradually over several weeks or months
Duration of Illness (Lifetime)
Chronic, lifelong disease
Cost of Treatment (Initial)
Moderate to high (initial diagnosis, specialist consultations, imaging, and medication)
Cost of Treatment (Lifetime)
High (ongoing medication, including expensive biologics for severe cases, physical therapy, regular monitoring, and potential surgeries)
Mortality Rate
Low directly from AS, but increased risk from complications like cardiovascular disease, respiratory issues, or severe spinal fractures
Risk of Secondary Damages
High (spinal deformity/kyphosis, restricted mobility, chronic pain, uveitis, inflammatory bowel disease, psoriasis, cardiovascular complications, osteoporosis, lung fibrosis)
Probability of Full Recovery
Very low (no known cure; management focuses on symptom control and preventing progression)
Underlying Disease Risk
High probability of co-occurring conditions such as uveitis (up to 40%), inflammatory bowel disease (5-10%), and psoriasis (5-10%). Strong genetic predisposition with HLA-B27 positivity in over 90% of cases.